Wegovy stories

Sep 9, 2026

Semaglutide linked to 40% reduction in asthma attacks in large real-world study

A large observational study found semaglutide (Ozempic/Wegovy) was associated with nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups compared to other treatments.

Sep 9, 20262 sources

Sep 7, 2026

Novo Nordisk's Wegovy helps 40% of young children lose enough weight to no longer be obese in trial

In a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide (Wegovy's active ingredient) were no longer obese after treatment, compared to the control group.

Sep 7, 20262 sources

Jul 17, 2026

India approves Wegovy for fatty liver disease treatment

India's drug regulator approved Novo Nordisk's obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease, expanding the drug's approved uses beyond weight loss.

Jul 17, 20261 source

May 7, 2026

Novo Nordisk Reports Positive Earnings on Oral Wegovy Development Progress

Novo Nordisk's stock price and earnings received a boost following less-negative news about the development of an oral version of its blockbuster weight loss drug Wegovy, marking progress in the company's efforts to create a pill formulation.

May 7, 20261 source

Top claims

▪A study led by Imperial College London found that semaglutide use was associated with a nearly 40% reduction in asthma attacks
▪The study led by Imperial College London found that semaglutide use was associated with a 20% reduction in chronic obstructive pulmonary disease flare-ups
▪GLP-1 receptor agonists, widely used for type 2 diabetes and obesity, may have anti-inflammatory effects and improve lung-related outcomes according to previous research

Topics

Drug Approval and Clinical Trials GLP-1 medications Supplementation Biohacking & optimization Evidence based supplementation Weight management Lifestyle, Wellness and Nutrition Respiratory health Novo Nordisk Pharma Childhood obesity Clinical trials Metabolic health Obesity treatment Corporate earnings Big Tech stock performance

Related entities

Ozempic Semaglutide Geriatric medicine India Liver disease